Table 1.
Baseline characteristics of 226 chronic hepatitis B patients.
| Variable | Degrees of hepatic steatosis | F value | P value | |||
|---|---|---|---|---|---|---|
| S0 (N = 119) | S1 (N = 76) | S2 (N = 22) | S3 (N = 9) | |||
| Male (n (%)) | 82 (68.91%) | 65 (85.53%) | 21 (95.46%) | 9 (100%) | 14.828 | 0.002 |
| Age | 29.50 ± 5.47 | 31.46 ± 8.40 | 29.41 ± 6.19 | 27.00 ± 7.38 | 2.063 | 0.106 |
| Age >40 (n (%)) | 6 (5.04%) | 15 (19.74%) | 1 (4.55%) | 0 (0%) | 13.28 | 0.004 |
| Course of disease | 8.57 ± 5.96 | 8.17 ± 5.29 | 8.98 ± 5.84 | 10.0 ± 9.50 | 0.327 | 0.806 |
| TC | 4.68 ± 0.80 | 5.15 ± 0.94 | 5.05 ± 1.11 | 5.43 ± 1.25 | 5.703 | 0.001 |
| TG | 0.56 ± 0.45 | 1.34 ± 0.68 | 1.42 ± 0.44 | 1.76 ± 0.63 | 13.180 | 0.001 |
| UA | 345.78 ± 69.38 | 370.10 ± 78.07 | 381.22 ± 101.58 | 429.69 ± 65.93 | 4.271 | 0.006 |
| Hyperuricaemia (n (%)) | 18 (15.13%) | 17 (22.37%) | 9 (40.91%) | 6 (66.67%) | 18.255 | 0.001 |
| Metabolic syndrome (n (%)) | 1 (0.84%) | 3 (3.95%) | 1 (4.55%) | 1 (11.11%) | 4.537 | 2.063 |
| GLU | 4.98 ± 0.50 | 5.35 ± 0.63 | 5.21 ± 0.36 | 5.67 ± 1.05 | 9.404 | 0.001 |
| ALT | 257.39 ± 175.17 | 186.14 ± 162.63 | 182.45 ± 108 | 137.44 ± 61.88 | 4.347 | 0.005 |
| AST | 126.72 ± 79.55 | 88.07 ± 67.82 | 76.95 ± 39.30 | 57.44 ± 24.10 | 7.560 | 0.001 |
| HBVlog10 (IU/mL) DNA | 7.17 ± 0.82 | 6.96 ± 0.98 | 7.23 ± 1.15 | 7.47 ± 0.69 | 1.224 | 0.302 |
| HBsAg (log IU/mL) | 4.12 ± 1.14 | 4.04 ± 0.91 | 4.23 ± 1.18 | 4.19 ± 1.13 | 1.273 | 0.283 |
| HBV genotype | 1.00 | 0.616 | ||||
| B | 35 (29.41%) | 23 (30.26%) | 7 (31.83%) | 3 (33.33%) | ||
| C | 78(65.55%) | 50 (65.79%) | 14(63.64%) | 6 (66.67%) | ||
| Mix | 6(5.04%) | 3 (3.95%) | 1 (4.55%) | 0 | ||
| BMI | 20.87 ± 1.96 | 24.98 ± 3.82 | 24.91 ± 3.91 | 25.78 ± 3.44 | 36.996 | 0.001 |
| BMI > 23 kg/m2 | 14 (11.76%) | 54 (71.05%) | 14 (63.64%) | 7 (77.77%) | 80.932 | 0.001 |